Nanosonics Limited (ASX:NAN) has announced the United States Food and Drug Administration (FDA) has granted a second 510(k) clearance for expanded endoscope indications for its CORIS System, expanding the range of endoscopes that can be reprocessed using the device.

Key Points

  • The FDA has granted a second 510(k) clearance for Nanosonics' CORIS System, covering expanded endoscope indications.
  • The expanded indications include a number of high-volume colonoscopes and gastroscopes.
  • The clearance builds on a prior De Novo clearance and a first 510(k) clearance already secured for the CORIS System.
  • The CORIS System is an automated endoscope channel cleaner designed to improve the cleaning of flexible endoscope channels.

Second FDA 510(k) Clearance for CORIS System

According to the filing, the FDA granted the second 510(k) clearance for the CORIS System, adding to the De Novo clearance and the first 510(k) clearance previously obtained. The latest clearance expands the range of endoscopes that can be reprocessed using the CORIS device. Nanosonics stated the clearance advances its roadmap to expand the CORIS System across a broader range of endoscope indications. The company described the CORIS System as an automated endoscope channel cleaner designed to improve the cleaning of flexible endoscope channels, which it characterised as a critical first step in the reprocessing of reusable endoscopes.

Expanded Indications Including High-Volume Colonoscopes and Gastroscopes

The filing disclosed that the expanded indications covered by the second 510(k) clearance include a number of high-volume colonoscopes and gastroscopes. Nanosonics stated that the company remains focused on progressively broadening the range of endoscopes that can be reprocessed with the CORIS System across all its key geographic markets. CEO and President Michael Kavanagh said the second FDA 510(k) clearance represents an important milestone for the CORIS System and demonstrates continued execution against the company's regulatory and commercialisation strategy and planned launch activities in the United States.

CORIS Regulatory and Commercialisation Strategy

Nanosonics described the second 510(k) clearance as part of its broader regulatory roadmap to expand the CORIS System across a wider range of endoscope indications. The filing stated that the company's planned launch activities in the United States are ongoing. Michael Kavanagh, CEO and President, was quoted in the filing as saying the company remains focused on progressively broadening the range of endoscopes that can be reprocessed with CORIS across all key geographic markets. The CORIS brand is a registered trade mark of Nanosonics Limited, and the filing was authorised by the Chair of the Nanosonics Limited Board.